Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 285

1.

Estradiol in breast cancer treatment: reviving the past.

Munster PN, Carpenter JT.

JAMA. 2009 Aug 19;302(7):797-8. doi: 10.1001/jama.2009.1223. No abstract available.

PMID:
19690316
[PubMed - indexed for MEDLINE]
2.

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.

Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA.

JAMA. 2009 Aug 19;302(7):774-80. doi: 10.1001/jama.2009.1204.

PMID:
19690310
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Endocrine therapy for the treatment of postmenopausal women with breast cancer.

Harichand-Herdt S, Zelnak A, O'Regan R.

Expert Rev Anticancer Ther. 2009 Feb;9(2):187-98. doi: 10.1586/14737140.9.2.187. Review.

PMID:
19192957
[PubMed - indexed for MEDLINE]
4.

Mechanisms of resistance to aromatase inhibitors.

Dowsett M, Martin LA, Smith I, Johnston S.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):167-72. Review.

PMID:
15982868
[PubMed - indexed for MEDLINE]
5.

Breast cancer: new aspects of adjuvant hormonal therapy.

Lohrisch C, Piccart M.

Ann Oncol. 2000;11 Suppl 3:13-25. Review. No abstract available.

PMID:
11079114
[PubMed - indexed for MEDLINE]
6.

Targeting breast cancer with hormonal treatment options.

Mellington TE, Fields MM.

Nurse Pract. 2008 May;33(5):17-22; quiz 22-3. doi: 10.1097/01.NPR.0000317483.12297.0a. Review. No abstract available.

PMID:
18458623
[PubMed - indexed for MEDLINE]
7.

Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.

Aapro M.

Anticancer Drugs. 2008 Mar;19 Suppl 2:S1. doi: 10.1097/01.cad.0000277610.08129.06. No abstract available.

PMID:
18337639
[PubMed - indexed for MEDLINE]
8.

Hormonal modulation in the treatment of breast cancer.

Adelson K, Germain D, Raptis G, Biran N.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):519-32, viii. doi: 10.1016/j.ecl.2011.05.011. Review.

PMID:
21889718
[PubMed - indexed for MEDLINE]
9.

Hormonal therapy for advanced breast cancer.

Rugo HS.

Hematol Oncol Clin North Am. 2007 Apr;21(2):273-91. Review.

PMID:
17512449
[PubMed - indexed for MEDLINE]
10.

[Biomarkers of endocrine therapy-resistance in breast cancers].

de Cremoux P, Debled M, Bonnefoi H, Cottu P.

Bull Cancer. 2010 Aug;97(8):951-63. doi: 10.1684/bdc.2010.1137. Review. French.

PMID:
20605764
[PubMed - indexed for MEDLINE]
11.

In brief.

Boughey JC, Buzdar AU, Hunt KK.

Curr Probl Surg. 2008 Jan;45(1):6-11. doi: 10.1067/j.cpsurg.2007.10.003. No abstract available.

PMID:
18206435
[PubMed - indexed for MEDLINE]
12.

Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies.

Dixon JM, Bundred N.

Eur J Surg Oncol. 2006 Mar;32(2):123-5. Epub 2005 Dec 27. Review. No abstract available.

PMID:
16380226
[PubMed - indexed for MEDLINE]
13.

[Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review].

Aziz M, Skougaard K, Kamby C, Nielsen DL.

Ugeskr Laeger. 2008 Jun 16;170(25):2248-52. Review. Danish. No abstract available.

PMID:
18565316
[PubMed - indexed for MEDLINE]
14.

The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.

Winer E.

Clin Adv Hematol Oncol. 2008 Aug;6(8):573-4. Review. No abstract available.

PMID:
18820598
[PubMed - indexed for MEDLINE]
15.

Addressing the future: combination with targeted therapies, adjuvant setting and beyond.

Goss PE.

Anticancer Drugs. 2008 Mar;19 Suppl 2:S3-5. doi: 10.1097/01.cad.0000251435.77758.82. Review.

PMID:
18337641
[PubMed - indexed for MEDLINE]
16.

Steroid metabolism in breast cancer.

Foster PA.

Minerva Endocrinol. 2008 Mar;33(1):27-37. Review.

PMID:
18277377
[PubMed - indexed for MEDLINE]
Free Article
17.

Endocrine therapy of metastatic breast cancer.

Rodríguez Lajusticia L, Martín Jiménez M, López-Tarruella Cobo S.

Clin Transl Oncol. 2008 Aug;10(8):462-7. Review.

PMID:
18667376
[PubMed - indexed for MEDLINE]
18.

Understanding the data, meeting patients' needs.

Kaufmann M.

Breast. 2008 Apr;17 Suppl 3:S1. doi: 10.1016/j.breast.2007.12.001. Epub 2008 Feb 20. No abstract available.

PMID:
18281217
[PubMed - indexed for MEDLINE]
19.

Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer.

Buzdar AU, Cuzick J.

J Clin Oncol. 2005 Nov 20;23(33):8544-6; author reply 8546-7. No abstract available.

PMID:
16293888
[PubMed - indexed for MEDLINE]
20.

Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss.

Zaman K, Thuerlimann B, Aebi S.

J Clin Oncol. 2013 Sep 20;31(27):3440-1. doi: 10.1200/JCO.2013.50.9737. Epub 2013 Aug 5. No abstract available.

PMID:
23918950
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk